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Purpose: Calcitonin was recently shown to counter the pro- 
gression of cartilage degradation in experimental models of os- 
teoarthritis. The beneficial effect was believed mediated indirectly 
by inhibition of subchondral bone resorption. We investigated 
whether calcitonin has direct effect on articular cartilage chon- 
drocytes. 
Methods: The Iocalisation and expression of the calcitonin re- 
ceptor in articular chondrocytes was investigated by immunhisto- 
chemistry and RT-PCR. Potential direct effects was tested in the 
articular cartilage explants model, where cartilage degradation 
was induced by cytokine stimulation of TNF-~ [20ng/ml] + onco- 
statin M (OSM) [10ng/ml], and cultured with salmon or human 
calcitonin simultaneously [0.0001-1mM]. The changes in carti- 
lage degradation were investigated in the conditioned medium by 
quantification of C-terminal telopeptides of collagen type II (CTX- 
II) and sulphated glycosaminoglycans release (sGAG) was tested 
by the Wielisa®-Kit. The effect of calcitonin was investigated in 
vivo using rats. Rats were administered with an oral dose of cal- 
citonin (2 mg/kg) bound to the carrier 5-CNAC (150 mg/kg). Colla- 
gen type II degradation was quantified in serum by measuring the 
released CTX-II and the degradation of bone by CTX-I, a marker 
of bone resorption, measuring fragments of collagen type I. 
Results: The calcitonin receptor was identified on articular chron- 
drocytes, both mRNA and protein forms. Culturing articular car- 
tilage explants in the presence of TNF-a and OSM resulted in a 
marked, 100-fold increase in CTX-II release compared to vehicle- 
treated controls (p<0.001). Addition of human or salmon calci- 
tonin to the explants culture [0.0001-1mM] in the concomitant 
presence of TNF-~ and OSM resulted in a significant and dose 
dependent inhibition of CTX-II release (p<0.01). At 100 nm and 
1 mM of calcitonin treatment in the presence of OSM and TNF- 
~, calcitonin very nearly abrogated collagen type II release, at 
day 13,16 and 19 of culture. In the absence of OSM and TNF- 
~, calcitonin significantly inhibited GAG release into the condi- 
tioned medium. Proteolytic activity was investigated by zymogra- 
phy. TNF-~ and OSM resulted in a strong up regulation of MMP- 
9 activity and expression. This increase in MMP activity was 
strongly attenuated by calcitonin at 100 nM and 1 mM, and the 
positive control GM6001 [25 mM], a the general MMP inhibitor, 
Under in vivo conditions, 4-day oral treatment with calcitonin in- 
duced a 95% decrease in serum CTX-II levels, i.e. chondrocyte- 
mediated cartilage degradation. The parallel effects of calcitonin 
treatment on bone resorption was indicated by a 50% decrease 
in urinary CTX-I excretion. 
Conclusions: These results suggest that calcitonin 1) acts di- 
rectly on articular chondrocytes; 2) inhibits MMP expression and 
the related collagen type II degradation; and 3) carries potentials 
for becoming a useful therapeutical option for patients with de- 
generative joint diseases. 
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GADD451~ IS NOVEL MEDIATOR OF MMP-13 GENE 
EXPRESSION DURING CHONDROCYTE HYPERTROPHY 
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Aim of Study: To define the role of growth arrest and DNA 
damage-inducible 451~ (GADD451~) in the regulation of chondro- 
cyte differentiation i the embryonic growth plate. 
Methods: Immortalized human chondrocytes (C-28/12) were 
treated with BMP-2 at 100 ng/ml for 1 h and total RNA was 
analyzed on the Affymetrix Gene Chip Human Genome U133A 
microarray and the highly expressed genes were confirmed in 
C28/12 cells and primary human chondrocytes by real-time PCR. 
ATDC5 cells and pellet cultures of murine rib growth plate chon- 
drocytes were grown under defined conditions as models of chon- 
drogenesis. Lentiviral siRNA delivery was performed to knock- 
down GADD451~ and the pcDNA3-Gadd451~-flag expression vec- 
tor was used to overexpress GADD451~. GADD451~ and MMP-13 
promoter activities were assessed using luciferase reporter con- 
structs. Mouse embryonic growth plates were examined by im- 
munohistochemistry and in situ hybridization. 
Results: We identified GADD451~ as a prominent early response 
gene induced by BMP-2 through a Smadl/Runx2-dependent 
pathway. Since this pathway is involved in skeletal development, 
we examined embryonic growth plates and observed expres- 
sion of GADD451~ mRNA coincident with Runx2 protein in pre- 
hypertrophic hondrocytes, whereas GADD451~ protein was local- 
ized in the nucleus in late stage hypertrophic hondrocytes where 
Mmp13 mRNA was expressed. In Gadd451~ knockout mouse 
embryos, defective mineralization and decreased endochondral 
growth accompanied eficient Mmpl 3 and Coll 0al gene expres- 
sion in the hypertrophic zone. Transduction of siRNA-GADD451~ 
in epiphyseal chondrocytes in vitro blocked terminal differenti- 
ation and the associated expression of Mmp13 and Coll0al 
mRNA. Finally, GADD451~ stimulated MMP-13 promoter activity 
in chondrocytes through c-Jun N-terminal kinase (JNK)-mediated 
phosphorylation of JunD partnered with Fra2 in synergy with 
Runx2. 
Discussion: Our results demonstrate a previously undiscovered 
role for GADD451~, which has been implicated in the stress re- 
sponse and cell survival during terminal differentiation of other 
cell types, as a critical mediator during endochondral ossifica- 
tion. The intracellular accumulation of GADD451~ protein in intact 
hypertrophic hondrocytes in the mouse embryonic growth plate 
and the effects of GADD451~ deficiency in vivo and in vitro indicate 
that GADD451~ is required for MMP-13 expression during the later 
stages of chondrocyte hypertrophy. Our findings on Runx2 syn- 
ergy provide a new concept regarding a temporal and spatial link 
between BMP-2-induced GADD451~ and the induction of MMP-13 
gene transcription via the JNK/JunD pathway at terminal stages. 
Furthermore, as we reported previously, GADD451~ is expressed 
in normal cartilage, increased in early stage osteoarthritis (OA), 
and decreased in late stage OA, particularly in the deep, calci- 
fied zone, where it may serve as an anti-apoptotic signal in cells 
with features of hypertrophic hondrocytes, suggesting a role in 
tidemark advancement. 
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